BRIEF-Astrazeneca gets orphan drug status for uveal melanoma treatment
April 17, 2015 at 02:07 AM EDT
* U.S. FDA has granted orphan drug designation for mek inhibitor selumetinib, for treatment of uveal melanoma Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 80 6749 1136)
